
Neurovalens Secures over £5 Million to Bring Neurostimulation to Healthcare
Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world’s most significant health challenges
By
CIO Applications Europe | Tuesday, July 21, 2020

Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world’s most significant health challenges.
FREMONT, CA: Belfast-based HealthTech firm Neurovalens raised £5.1m in funding, led by IQ Capital. Wharton Asset Management Company, The Angel CoFund (ACF), Techstart Ventures, Clarendon Fund Managers, and the Government’s Future Fund also contributed to the funding round.
Neurovalens’ technology was created in collaboration with research facilities at the University of California San Diego and is designed to influence the brainstem and hypothalamus in a non-invasive way to cure or treat neurological diseases, without the need for implanted electrodes.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
CEO and co-founder of Neurovalens, Dr. Jason Mckeown said: “We are delighted to receive this investment and support at such a critical time for our business.
“Our work in the US and the success of the trials we have run to date have demonstrated the potential of our technology and encouraged us to pursue other applications. With this financing and the backing of our investors we can accelerate our mission of delivering effective and non-invasive solutions for some of the most common and debilitating medical conditions.”
The funding will be used for clinical trial research and development in the UK and abroad, as well as hiring additional staff. Neurovalens’ technology is currently going through FDA and EU regulatory approvals. The firm is already in the final phase of trials for obesity and aims to have permission for insomnia and anxiety devices in the next 12 months, with diabetes trials set for 2021.
Tim Mills, the Managing Partner of the Angel CoFund, said: “The Neurovalens team have developed a truly innovative technique to help people combat an array of health challenges.
“As such, they are a rare example of a startup that really has the potential to fundamentally affect the sector they are in, changing how clinicians treat certain conditions. It is exciting to see the team at Neurovalens continue to grow and the success of their clinical trials, and we look forward to seeing the team continue to push boundaries in health tech.”
More in News
Weekly Brief
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from CIO Applications Europe
THANK YOU FOR SUBSCRIBING


